Atazanavir

ArtNr	HY-17367-10mM
Hersteller	MedChem Express
CAS-Nr.	198904-31-3
Menge	10 mM/1 mL
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 50 mg 5 mg
Kategorie	Neuroscience Aging & Neurological Disorders Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.86
Citations	[1]Havlir DV, et al. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis. 2004 Jun 1;38(11):1599-604.\|[2]Wood R. Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96.\|[3]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.\|[4]Zhang G, et al. Long-term oral atazanavir attenuates myocardial infarction-induced cardiac fibrosis. Eur J Pharmacol. 2018 Jun 5;828:97-102.\|[5]Fukushima K, et al. Effect of serum lipids on the pharmacokinetics of atazanavir in hyperlipidemic rats. Biomed Pharmacother. 2009 Nov;63(9):635-42.\|[6] Pyrko P, et al. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res. 2007 Nov 15;67(22):10920-8. \|[7] Alomar FA, et al. Efavirenz, atazanavir, and ritonavir disrupt sarcoplasmic reticulum Ca2+ homeostasis in skeletal muscles. Antiviral Res. 2021 Mar;187:104975. \|[8] Robillard KR, et al. Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract. Antimicrob Agents Chemother. 2014;58(3):1713-22. Aging Cell. 2022 Dec 20;e13750.\|Antimicrob Agents Chemother. 2020 Aug 20;64(9):e00872-20.\|Faculty of Pharmacy in Hradec Králové Department of Pharmacological and Toxicology. University of Oxford. 2019 Jul.\|Int J Antimicrob Agents. 2019 Dec;54(6):814-819.\|PLoS Biol. 2020 Jan 16;18(1):e3000599. \|Research Square Print. 2022 May.\|bioRxiv. 2020 Apr.\|Curr Protoc. 2021 Feb;1(2):e32.\|Nat Commun. 2020 Apr 14;11(1):1792.\|Nat Commun. 2020 Sep 4;11(1):4417.\|Signal Transduct Target Ther. 2021 May 29;6(1):212.
Smiles	O=C(OC)N[C@@H](C(C)(C)C)C(NN(CC1=CC=C(C2=NC=CC=C2)C=C1)C[C@H](O)[C@H](CC3=CC=CC=C3)NC([C@H](C(C)(C)C)NC(OC)=O)=O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	BMS-232632
Versandbedingung	Gekühlt
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-anti-virus
Manufacturer - Targets	Cytochrome P450; Endogenous Metabolite; HIV; HIV Protease; P-glycoprotein; SARS-CoV; Toll-like Receptor (TLR)
Shipping Temperature	Blue Ice
Storage Conditions	-20°C, 3 years (Powder)
Molecular Weight	704.86
Product Description	Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death[1][2][3][4][5][6][7][8].
Manufacturer - Research Area	Cancer; Infection; Cardiovascular Disease
Solubility	DMSO: 83.33 mg/mL (ultrasonic)
Manufacturer - Pathway	Anti-infection; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease
Isoform	CYP3; HIV-1
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-17367-10mM-safety-datasheet.pdf